Nonrandom translocations with breakpoint at band q21 on chromosome 18 might cause bcl-2 gene deregulation and might contribute to neoplastic transformation in human lymphomas. As the pattern of expression of bcl-2 in hematopoietic cells is still unclear, we have measured the level of the corresponding messenger RNA (mRNA) in a variety of myeloid and lymphoid cell malignancies not usually associated with the t(14;18) translocation. Molecular genetic analysis showed that bcl-2 was rearranged in only 2 of 77 patients: one was affected by hairy cell leukemia and one by diffuse small cleaved cell lymphoma with peripheral blood invasion. Although in rare cases of myeloid leukemia fairly high levels HE PUTATIVE oncogene bcl-2 is a transcriptional T unit that was found at the breakpoint site on chromosome 18 in lymphomas characterized by the t(14;18) (q32; q21) chromosomal transl~cation.'-~ In most cases, the breaks on chromosome 18 occur within an area spanning 2.8 kb, indicated as major breakpoint region (mbr). Less frequently, breakpoints are clustered in a region approximately 30 kb apart at the 3' side! In both cases, bcl-2 is moved from chromosome 18 to chromosome 14 and, on the derivative chromosome 14, it is juxtaposed head-to-tail to Ig heavy chain gene sequences. Rare variant translocations have also been described in which either chromosome 2 or chromosome 22 substitute for chromosome 14 in reciprocal translocations involving chromosome 18. In these cases, the breaks on chromosome 18 are localized at the 5' side of the gene and bcl-2 is juxtaposed, respectively, to K or A light chain gene sequence^.^-^ Although the function of the protein encoded by bcl-2 is still unknown,8s9 the activation of this gene might have a role in the majority of follicular lymphomas and in a significant percentage of diffise follicle center cell lymphomas.1° However, the mechanism by which the translocated bcl-2 might contribute to neoplastic transformation remains obscure. The coding region of the gene is not interrupted, and even though hybrid bcl-2/Ig transcripts have been found, the presence of translation termination codons would not allow the generation of a chimeric protein. 
Nonrandom translocations with breakpoint at band q21 on chromosome 18 might cause bcl-2 gene deregulation and might contribute to neoplastic transformation in human lymphomas. As the pattern of expression of bcl-2 in hematopoietic cells is still unclear, we have measured the level of the corresponding messenger RNA (mRNA) in a variety of myeloid and lymphoid cell malignancies not usually associated with the t(14;18) translocation. Molecular genetic analysis showed that bcl-2 was rearranged in only 2 of 77 patients: one was affected by hairy cell leukemia and one by diffuse small cleaved cell lymphoma with peripheral blood invasion. Although in rare cases of myeloid leukemia fairly high levels HE PUTATIVE oncogene bcl-2 is a transcriptional T unit that was found at the breakpoint site on chromosome 18 in lymphomas characterized by the t(14;18) (q32; q21) chromosomal transl~cation.'-~ In most cases, the breaks on chromosome 18 occur within an area spanning 2.8 kb, indicated as major breakpoint region (mbr). Less frequently, breakpoints are clustered in a region approximately 30 kb apart at the 3' side! In both cases, bcl-2 is moved from chromosome 18 to chromosome 14 and, on the derivative chromosome 14, it is juxtaposed head-to-tail to Ig heavy chain gene sequences. Rare variant translocations have also been described in which either chromosome 2 or chromosome 22 substitute for chromosome 14 in reciprocal translocations involving chromosome 18. In these cases, the breaks on chromosome 18 are localized at the 5' side of the gene and bcl-2 is juxtaposed, respectively, to K or A light chain gene sequence^.^-^ Although the function of the protein encoded by bcl-2 is still unknown,8s9 the activation of this gene might have a role in the majority of follicular lymphomas and in a significant percentage of diffise follicle center cell lymphomas.1° However, the mechanism by which the translocated bcl-2 might contribute to neoplastic transformation remains obscure. The coding region of the gene is not interrupted, and even though hybrid bcl-2/Ig transcripts have been found, the presence of translation termination codons would not allow the generation of a chimeric protein. " Mutations in the open reading frame of the translocated bcl-2 have been found in cell lines and, more recently, in DNA extracted from the affected lymph nodes of some patients.lZJ3 While the biologic significance of somatic mutations that alter the protein encoded by bcl-2 has to be established, several investigators proposed that, as a result of chromosomal translocations, bcl-2 might be deregulated and the corresponding messenger RNA (mRNA) might be constitutively produced in cells in which the gene should be ~i l e n t .~.~J~ However, most data that have been presented to support this hypothesis have been obtained studying a small number of established cell lines, and the regulation of bcl-2 in hematopoietic cell differentiation is still controversia1.15J6 As the relationship between the expression level and the differentiation stage seems to be a crucial issue, we thought it would be useful to study the pattern of expression of this gene in a series of leukemic cell populations pertaining to different lineages and representative of various differentiation stages. Although we focused on cell population in which rearrangements involving bcl-2 were not to be expected, molecular genetic analysis was exploited to confirm that bcl-2 locus was intact. Because a role of bcl-2 in the control of cell proliferation was initially ~uggested,'~-*O the expression level of c-myc oncogene and of histone H3 gene was also determined.
MATERIALS AND METHODS
In most cases, heparinized bone marrow or peripheral blood samples were obtained from newly diagnosed patients before chemotherapy. In some cases, specimens came from relapsed patients who did not receive any chemotherapy for at least 30 days. Leukocytes were collected after erytrocyte sedimentation and, when necessary, mononuclear cells were separated by isopicnic Ficoll-Hypaque density gradient centrifugation to obtain homogeneous leukemic cell populations. Only samples containing at least 70% tumor cells were selected for inclusion in this study. Diagnosis, made according to cytologic criteria on May-Griinwald/Giemsa-stained smears, was confirmed by means of standard cytochemical reactions (periodic acid-Schiff [PAS], Sudan Black, myeloperoxidase, acid phosphatase, naphtol AS-D-cloroacetate esterase, a-naphtil acetate esterase). In all patients affected by hairy cell leukemia (HCL) a strongly positive tartrate-resistant acid phosphatase activity was shown. The immunophenotypic features of the cells were determined by direct immunofluorescence and cytofluorograph readings (FACStar; Becton Dickinson, Mountain View, CA) using the following monoclonal antibodies (MoAbs): OK Ial (HLA-DR), OKT3 (CD3), OKT4 (CD4), OKT6 (CDla), OKT8 (CD8), and OKT11 (CD2) Patient samples and cell characterization. For personal use only. on October 25, 2017. by guest www.bloodjournal.org From (Orthodiagnostic, Raritan, NJ); Leu1 (CD5), Leu9 (CD7), Leu12 (CD19), Leu16 (CD20), Leu17 (CD38), TCR-1 (T-cell receptor-1) (Tiap) (Becton Dickinson); B2 (CD21), My4 (CD14), My7 (CD13), My9 (CD33), and J5 (CD10) (Coulter Corporation, Hialeah, FL). Terminal deoxynucleotide transferase (Tdt) was determined by indirect immunofluorescence using a commercial assay kit (BRL, Gaithersburg, MD). At the RNA level, cell characterization was completed by studying the expression of a series of genes regulated in a differentiation-dependent manner (k heavy chain; K and A light chain; TCR a, p, and y chain; HLA-DR-associated invariant chain). In lymphoid malignancies, the lineage origin of the cells was confirmed by showing clonal rearrangements of Ig and TCR genes and, in addition to flow cytometric data, the relative intensities of germline and rearranged bands were exploited to estimate the percentage of leukemic cells in each specimen. In acute (both lymphoid and myeloid) leukemias and in chronic myelogenous leukemia (CML), cytogenetic analysis was routinely performed using G banding, by means of standard techniques.
The arrangement and the expression of Ig genes were studied by means of the following probes: (1) a 6-kb genomic fragment including JH 1-6 genes plus flanking sequences; (2) a 1.2-Kb EcoRI subgenomic fragment containing part of the first and all of the second and third exons of the p heavy chain genez1; (3) a 2.5-kb EcoRI genomic fragment comprising the constant region of K light chain gene"; and (4) The expression of c-myc and H3-histone genes was studied using, respectively, a 1.2-kb Pst I cDNA fragment and a 2.1-kb EcoRI genomic fragment.z8, 29 The expression of p-actin gene was determined by means of a BamHI cDNA fragment. 30 The arrangement of bcl-2 gene was studied by using the following probes: (1) a 2.8-kb HindIIIIEcoRI genomic fragment (probe pFL3) corresponding to the mbr region within the 3' noncoding segment of the second exon of the gene3; (2) a 4-kb EcoRI fragment corresponding to the minor breakpoint cluster region (mcr) more than 20 kb downstream of the second exon, including probe pFL2 plus flanking sequences4; and (3) a 1.6-kb EcoRI fragment (probe pB16) corresponding to the 3' part of the first exon of b~l -2 .~
The expression level of bcl-2 was determined by using probe pFL3.
High molecular weight DNA, extracted as previously described?] was cleaved with a series of restriction endonucleases (BRL), size fractionated on a 0.8% agarose gel, and transferred to Gene Screen Plus nylon filters (New England Nuclear, Boston, MA) essentially as described by Southern.32 DNAs were digested, separately, with BumHI, EcoRI, and HindIII restriction endonucleases to search rearrangements affecting Ig heavy chain and TCR p chain gene. BumHI and EcoRI were used to determine the organization of TCR y gene. Digestion with BumHI was considered sufficient to determine the arrangement of K light chain genes. Finally, we used HindIII and BumHI (probes pFL2 and pFL3) or HindIII and EcoRI (probe pB16) to exclude rearrangements of bcl-2 gene.
Total RNA was extracted in the presence of guanidinium thi~cyanate?~ and the concentration was determined spectrophotometrically by the absorbance at 260 nmol/L. Samples containing 15 kg of RNA were denatured at 65°C in 50% formamide, electrophoresed on a 1.1% agarose gel with 6% formaldehyde, and Molecular probes.
Nucleic acids analysis. transferred to Hybond-N membrane (Amersham Corp, Arlington Heights, IL) using an electroblot apparatus (BioRad, Richmond, CA) as previously de~cribed.3~ The intensity of 28s and 18s ribosomal RNA bands, visualized by W excitation, was measured in etidium bromide-stained gels as well as on the membranes to exclude RNA degradation or artifacts due to uneven RNA transfer.
Probes were radiolabeled with 32P dCTP by using the randompriming labeling technique described by Feinberg and Vog e l~t e i n .~~ In Southern and Northern blot experiments, filters were prehybridized for 6 hours at 65°C in 6 X SSC (1 x SSC = 0.15 mol/L NaCI, 0.015 mol/L Na3 citrate, pH 7.0), 10 mmol/L EDTA, 0.5% sodium dodecyl sulfate (SDS), 5 x Denhardt solution ( l x Denhardt solution = 0.02% bovine serum albumin, 0.02% polyvinyl pyrrolidone, 0.02% ficoll), and 100 pg/mL sonicated salmon sperm DNA. Hybridizations were performed overnight under the same conditions, besides adding dextran sulphate to a final concentration of 10% in Northern blots. Filters were washed in 0.2 X SSC for 6 hours at 65°C and exposed at -80°C with intensifying screens. At various exposure times, the intensity of autoradiographic bands was quantified by laser densitometry using an Ultroscan XL densitometer (Pharmacia LKB, Uppsala, Sweden). The level of bcl-2 mRNA, determined after normalization to (Table 2) were loaded, respectively, on lanes 1 through 4. In (C), patients on lanes 1 through 5 correspond to patients 15,18,16,13, and 14 in Table 5 . In (D), RNAs loaded on lanes 1 through 5 came from patients 1,2,8,6, and 7 of Table 6 . T-ALL, T-cell acute lymphoblastic leukemia; MM, mukiple myeloma; PCL, plasma cell leukemia.
f3-actin, was measured as units of expression relative to noma1 peripheral blood mononuclear cells (mean value of four healthy donors). The expression level of other genes was expressed in arbitrary units.

RESULTS
Overall, 77 patients were studied: 19 were affected by myeloid leukemias, 11 by leukemias pertaining to the T lineage, and 47 by B-cell neoplasms at various differentiation stages.
The results obtained with patients affected by myeloid leukemias are summarized in Table 1 . Ten patients had acute myeloid leukemia (AML) and nine had chronic myeloid leukemia (CML). Except for patient 7, both Ig and TCR genes were in a germline configuration. Neither translocations involving chromosome 18 nor bcl-2 gene rearrangements were found in this group of patients and, in most cases, bcl-2 mRNA was either absent or barely detectable. Only one patient with AML (no. 10) and one with blast crisis of CML (no. 19) had significant amounts of an 8.5-kb mRNA (3.36 and 8.99 relative intensity units, respectively). Neither patient expressed the 5.5-kb mRNA at detectable levels. bcl-2 mRNA was also expressed, although at lower levels, in RNA extracted from the HL-60 cell line (Fig 1A) . No obvious correlation was found with the expression of c-myc or histone H3.
The results obtained with a group of patients affected by T-cell neoplasms are shown in Table 2 . In only one case (patient 2) were we not able to show any rearrangement of the TCR y gene with the probe we used; the T-lineage origin of the cells, however, was proven by the high expression of full-length TCR a and @ mRNAs, as well as by the immunophenotypic features of the cells. All the other patients had both TCR p and TCR y genes rearranged. In patient 7, a nonproductive rearrangement involving Ig heavy chain gene locus was also present. In patients 1 through 8, cytogenetic analysis did not show any translocation involving chromosome 18. In all cases, bcl-2 gene was germline. Low levels of bcl-2 mRNA were found in three patients with chronic T-cell leukemias, whereas less differentiated T-cell leukemias were highly heterogeneous with regard to bcl-2 gene expression. The results are shown, in part, in Fig 1B. The highest levels (15.42 and 16.21 relative intensity units) were found in two cases of acute lymphoblastic leukemia (ALL) (patients 7 and 8, Table 2 ). Neither -- (Table 3) . At the RNA level, both patients expressed the TCR y gene. The expression of bcl-2 followed a different pattern in B-cell malignancies. Nine patients in our series were affected by "common" (cALLa positive) ALL. All of these patients had rearranged Ig heavy chain genes and, in most cases, K light chain genes were germline (Table 4) . At the RNA level, p heavy chain gene was consistently expressed, whereas light chain genes were silent. In one case (no. 6), unexpectedly low levels of A light chain mRNA were found. Typically, the HLA-DR-associated invariant chain was expressed in all cases. In all patients but one (patient 4) the Table 4 . bcl-2 G TCR p gene was in a germline configuration. Except for a faint band corresponding to a single mRNA species of 8.5 kb found in patient 9 (not shown), bcl-2 mRNA was undetectable in these patients. In some cases, e-myc and histone H3 mRNAs were expressed at high level.
+++ +++
The expression of bcl-2 gene in B-cell lymphoproliferative disorders is shown in Table 5 . Patients 1 through 20 were affected by B-cell chronic lymphocytic leukemia (B-CLL); all these patients had leukocytosis with a high percentage of monoclonal B cells. All of them had rearranged Ig genes and expressed either K or A light chain genes, as well as the invariant chain gene. Consistent with the kinetic characteristics of the cells, c-myc and histone H3 mRNAs were either absent or expressed at low levels. In all cases, bcl-2 appeared to be germline. All patients in this group expressed bcl-2. However, in patients 1 through 4, the level of bcl-2 mRNA was lower than in peripheral blood mononuclear cells from healthy donors, and only one band of 8.5 kb was detectable. In patients 5 through 20, the expression was higher and both 8.5-and 5.5-kb mRNAs were present (Fig IC) . Still, a remarkable variability characterized the mRNA level in these patients (mean * SD, 14.97 * 8.76; range, 4.15 to 30.92). Two patients affected by prolymphocytic leukemia (PLL) were included in our series (nos. 21 and 22); in both, relatively high levels of bcl-2 mRNA were found (16.95 and 18.66 U, respectively). Three additional patients had low-grade non-Hodgkin's lymphomas (NHL) with peripheral blood invasion, classified as small lymphocytic-type (nos. 23 and 25) or diffuse small cleaved cells (no. 24) according to the working formulation.36 In patients 23 and 25, the heavy chain class switch already took place, and p heavy chain mRNA was absent; these patients' cells expressed, respectively, ci and y heavy chains (not shown). In patient 23, high levels of bcl-2 mRNA were found (24.87 U) despite the presence of a germline gene. In patient 24, characterized by a rearranged bcl-2, the gene was expressed at lower levels. In this patient, a rearranged band of 4.6 kb was found in HindIII-digested DNA using both the pFL3 and JH probes (not shown). Only two of five patients with HCL expressed bcl-2 mRNA at detectable levels. In one of them (patient 26), rearranged bands were found using the pFL2 probe in DNA digested with Hind111 (18 and 6.7 kb) and BamHI (22 and 7 kb) 
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Finally, bcl-2 was highly expressed in three of nine patients with plasma cell neoplasms (Fig 1D) . One of them (patient 8, Table 6 ) had several atypical features, as most tumor cells were morphologically immature plasmablasts that expressed the HLA-DR-associated invariant chain and secreted low amounts of monoclonal IgG A. However, in patients 6 and 7, bone marrow plasma cells, although highly atypical, secreted large amounts of IgG K and IgA K, respectively. In all these patients, bcl-2 gene was germline.
DISCUSSION
We have found significant levels of bcl-2 mRNA in only 2 of 19 cases of myeloid leukemia, and our data confirm that the expression of bcl-2 is mainly restricted to lymphoid cells. Furthermore, the present data confirm that bcl-2 RNA extracted from five patients with HCL was hybridized to probe pFL-3 (upper panel) and to p a d i n probe (lower panel). Patients on lanes 1 through 5 correspond, respectively, to patients 29,30,27,28, and 26 in Table 5 .
For One of the patients with a rearranged bcl-2 gene was affected by HCL. Diagnosis, suggested by pancytopenia and splenomegaly, was confirmed by the morphologic and cytochemical features of the cells, as well as by bone marrow and spleen histopathology. Typically, the patient obtained a first remission after splenectomy and, at relapse, a second prolonged remission (4+ years) was obtained with recombinant a-2b interferon. At our knowledge, the presence of bcl-2 gene rearrangements in this disorder has not been reported previously.
+I-
The expression of bcl-2 in T lymphocytes has not been extensively studied, so far, and low levels of bcl-2 mRNA have been found in a small number of cell lines at various differentiation stages.11J7 Our data show that high expression levels can be found in some immature T-cell populations. Although more cases should be studied, the highest expression might be typical of a subset of CD4lCD8-negative T cells that express the ylS antigen receptor.
With regard to B-cell development, previous studies indicated that bcl-2 is expressed in human pre-B-cell lines, but is downregulated with m a t~r a t i o n .~J~ These findings suggested that bcl-2, if maintained transcriptionally active beyond the pre-B stage, might contribute to the neoplastic transformation in lymphoma cells carrying the t( 14;18) translocation. However, a somehow different scenario in which bcl-2 gene activation occurs at a more advanced maturation stage seems more likely. As a matter of fact, bcl-2 is silent in most pre-B-cell leukemias and the highest levels are found in a large subgroup of chronic, more differentiated leukemias. These discrepancies, perhaps, can be partially explained considering that our data were obtained studying unmanipulated human leukemic cells, whereas most cited studies were performed on established cell lines. Species-related factors might also contribute to explain differences between murine and human cells. Finally, it has been reported that bcl-2 is silent in terminally differentiated plasma cell^.^^^^^^^^ Although, in general, the expression of bcl-2 declines beyond the stage represented by CLL and PLL, high levels can still be found in some human plasma cell neoplasms.
Although the highest expression of bcl-2 is found in the group of patients with chronic B-lineage leukemias as a whole, a remarkable variability exists among individual patients. So far, we could not correlate the differences in bcl-2 mRNA levels with any particular phenotypic feature of the cells. To have insight into the possible role of bcl-2 in normal and neoplastic cells, future research should focus on the remarkable disparity that characterizes phenotipically more mature B-cell leukemias. In follicular and diffuse large cell and mixed cell lymphomas, the rearrangement of bcl-2 is associated with a poor prognosis.39 More cases should be studied and a longer follow-up would be necessary to establish whether, even in the absence of gene rearrangements, any prognostic value can be attributed to the expression of bcl-2. The expression of bcl-2, indeed, is not specific for lymphomas characterized by the t( 14;18) translocatiod6 and, regardless of the underlying mechaFor personal use only. on October 25, 2017. by guest www.bloodjournal.org From nisms, high levels of bcl-2 gene product might well influence the behavior of both normal and neoplastic cells. A role of bcl-2 in cell proliferation has been propo~ed,'~-*~ and we also observed a slight increase of bcl-2 mRNA levels in peripheral blood mononuclear cells after stimulation with phytohemagglutinin. However, in general, the absence of any correlation with the expression of c-myc and histone H3 would argue against this possibility. More likely, at least in neoplastic cells pertaining to the B lineage, bcl-2 in itself might provide a survival A death-sparing effect of bcl-2 would be consistent with the long life span of the neoplastic cells in chronic B-cell leukemias as well as in indolent low-grade lymphomas. This property, perhaps, might also contribute to explain the low sensitivity to chemotherapy that is typical of these disorders. For personal use only. on October 25, 2017. by guest www.bloodjournal.org From
